1
|
Abstract
Lack of effective targeted therapies often contributes to poor clinical outcomes of aggressive malignancies associated with drug resistance, angiogenesis and metastasis. Literature mining portrays the major role of ADAM17 in cancer and inflammatory diseases. However, it is quite challenging to design a candidate drug for targeting ADAM17 due to its structural similarity with the catalytic domain of the matrix metalloproteases (MMPs). The present study reports the protein-protein interaction analysis of ADAM17, along with the molecular docking and MD simulation studies for the screened compounds. Our analysis confirms the association of ADAM17 with numerous oncogenes that facilitates cancer progression and inflammation, especially the members of the Notch, receptor tyrosine kinase (RTK) and TNFα pathways. The outcome provides evidence that the prevalent protease ADAM17 could attribute to cancer signaling regulation though the shedding of various inflammatory and oncogenic molecules. We have also exploited the analogues of the existing inhibitors, with an aim at discovering a potent molecule, which could be repurposed as a drug against ADAM17 inflicted cancer progression. Upon stringent screening, we delineated our choice into two specific compounds (I6 and I9; analogues of IK862, a type of y-lactam hydroxamates), possessing the lowest binding energy (-9.1 Kcal/mol), stable MD-simulation studies and superior pharmacodynamic properties. The current information illustrates the avenue to persuade further research on targeting ADAM17 with small molecular compounds (I6 and I9) in cancer therapeutics.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Plaboni Sen
- Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, India
| | - Thirukumaran Kandasamy
- Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, India
| | - Siddhartha Sankar Ghosh
- Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, India.,Centre for Nanotechnology, Indian Institute of Technology Guwahati, Guwahati, Assam, India
| |
Collapse
|
2
|
Wang K, Xuan Z, Liu X, Zheng M, Yang C, Wang H. Immunomodulatory role of metalloproteinase ADAM17 in tumor development. Front Immunol 2022; 13:1059376. [PMID: 36466812 PMCID: PMC9715963 DOI: 10.3389/fimmu.2022.1059376] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2022] [Accepted: 11/03/2022] [Indexed: 12/25/2023] Open
Abstract
ADAM17 is a member of the a disintegrin and metalloproteinase (ADAM) family of transmembrane proteases involved in the shedding of some cell membrane proteins and regulating various signaling pathways. More than 90 substrates are regulated by ADAM17, some of which are closely relevant to tumor formation and development. Besides, ADAM17 is also responsible for immune regulation and its substrate-mediated signal transduction. Recently, ADAM17 has been considered as a major target for the treatment of tumors and yet its immunomodulatory roles and mechanisms remain unclear. In this paper, we summarized the recent understanding of structure and several regulatory roles of ADAM17. Importantly, we highlighted the immunomodulatory roles of ADAM17 in tumor development, as well as small molecule inhibitors and monoclonal antibodies targeting ADAM17.
Collapse
Affiliation(s)
- Kai Wang
- Key Laboratory of Epigenetics and Oncology, Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, China
| | - Zixue Xuan
- Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, China
| | - Xiaoyan Liu
- Key Laboratory of Epigenetics and Oncology, Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, China
| | - Meiling Zheng
- Key Laboratory of Epigenetics and Oncology, Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, China
| | - Chao Yang
- National Engineering Research Center for Marine Aquaculture, Institute of Innovation & Application, Zhejiang Ocean University, Zhoushan, China
| | - Haiyong Wang
- Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| |
Collapse
|
3
|
Guan C, Zhang HF, Wang YJ, Chen ZT, Deng BQ, Qiu Q, Chen SX, Wu MX, Chen YX, Wang JF. The Downregulation of ADAM17 Exerts Protective Effects against Cardiac Fibrosis by Regulating Endoplasmic Reticulum Stress and Mitophagy. Oxid Med Cell Longev 2021; 2021:5572088. [PMID: 34035876 DOI: 10.1155/2021/5572088] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Revised: 03/27/2021] [Accepted: 04/09/2021] [Indexed: 02/08/2023]
Abstract
Background A disintegrin and metalloproteinase 17 (ADAM17) is a transmembrane protein that is widely expressed in various tissues; it mediates the shedding of many membrane-bound molecules, involving cell-cell and cell-matrix interactions. We investigated the role of ADAM17 within mouse cardiac fibroblasts (mCFs) in heart fibrosis. Methods mCFs were isolated from the hearts of neonatal mice. Effects of ADAM17 on the differentiation of mCFs towards myofibroblasts and their fibrotic behaviors following induction with TGF-β1 were examined. The expression levels of fibrotic proteins, such as collagen I and α-SMA, were assessed by qRT-PCR analysis and western blotting. Cell proliferation and migration were measured using the CCK-8 and wound healing assay. To identify the target gene for ADAM17, the protein levels of the components of endoplasmic reticulum (ER) stress and the PINK1/Parkin pathway were assessed following ADAM17 silencing. The effects of ADAM17 silencing or treatment with thapsigargin, a key stimulator of acute ER stress, on mCFs proliferation, migration, and collagen secretion were also examined. In vivo, we used a mouse model of cardiac fibrosis established by left anterior descending artery ligation; the mice were administered oral gavage with a selective ADAM17 inhibitor (TMI-005) for 4 weeks after the operation. Results We found that the ADAM17 expression levels were higher in fibrosis heart tissues and TGF-β1-treated mCFs. The ADAM17-specific siRNAs decreased TGF-β1-induced increase in the collagen secretion, proliferation, and migration of mCFs. Knockdown of ADAM17 reduces the activation of mCFs by inhibiting the ATF6 branch of ER stress and further activating mitophagy. Moreover, decreased ADAM17 expression also ameliorated cardiac fibrosis and improved heart function. Conclusions This study highlights that mCF ADAM17 expression plays a key role in cardiac fibrosis by regulating ER stress and mitophagy, thereby limiting fibrosis and improving heart function. Therefore, ADAM17 downregulation, within the physiological range, could exert protective effects against cardiac fibrosis.
Collapse
|
4
|
Murumkar PR, Ghuge RB, Chauhan M, Barot RR, Sorathiya S, Choudhary KM, Joshi KD, Yadav MR. Recent developments and strategies for the discovery of TACE inhibitors. Expert Opin Drug Discov 2020; 15:779-801. [PMID: 32281878 DOI: 10.1080/17460441.2020.1744559] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
INTRODUCTION TNF-α plays a central role in certain autoimmune diseases as well as in inflammation. The current strategy for excluding TNF-α from circulation is to selectively inhibit TNF-α converting enzyme (TACE), an enzyme that cleaves mTNF-α to active TNF-α. Various TACE inhibitors have been discovered by using different strategies to control inflammatory diseases, cancer, and cardiac hypertrophy. AREAS COVERED The present article summarizes the design and discovery of novel TACE inhibitors that have been reported in the literature since 2012 onwards. It also includes some reports concerning the new role that TACE plays in cancer and cardiac hypertrophy. EXPERT OPINION So far, undertaken studies that have looked to design and develop small TACE inhibitors have been discouraging due to the failure of any TACE inhibitors to hit the market. However, some of the latest developments, such as with tartrate-based inhibitors, has given hope to the potentiality of a viable novel selective TACE inhibitor therapeutic in the future. Indeed, some of the novel peptidomimetics and monoclonal antibodies have great potential to pave the way for an effective and safe therapy by selectively inhibiting TACE enzyme.
Collapse
Affiliation(s)
- Prashant R Murumkar
- Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda , Vadodara, India
| | - Rahul B Ghuge
- Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda , Vadodara, India
| | - Monica Chauhan
- Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda , Vadodara, India
| | - Rahul R Barot
- Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda , Vadodara, India
| | - Sharmishtha Sorathiya
- Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda , Vadodara, India
| | - Kailash M Choudhary
- Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda , Vadodara, India
| | - Karan D Joshi
- Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda , Vadodara, India
| | - Mange Ram Yadav
- Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda , Vadodara, India
| |
Collapse
|
5
|
Boiteau JG, Ouvry G, Arlabosse JM, Astri S, Beillard A, Bhurruth-Alcor Y, Bonnary L, Bouix-Peter C, Bouquet K, Bourotte M, Cardinaud I, Comino C, Deprez B, Duvert D, Féret A, Hacini-Rachinel F, Harris CS, Luzy AP, Mathieu A, Millois C, Orsini N, Pascau J, Pinto A, Piwnica D, Polge G, Reitz A, Reversé K, Rodeville N, Rossio P, Spiesse D, Tabet S, Taquet N, Tomas L, Vial E, Hennequin LF. Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis. Bioorg Med Chem 2017; 26:945-956. [PMID: 28818461 DOI: 10.1016/j.bmc.2017.07.054] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Revised: 07/17/2017] [Accepted: 07/28/2017] [Indexed: 01/15/2023]
Abstract
Targeting the TNFα pathway is a validated approach to the treatment of psoriasis. In this pathway, TACE stands out as a druggable target and has been the focus of in-house research programs. In this article, we present the discovery of clinical candidate 26a. Starting from hits plagued with poor solubility or genotoxicity, 26a was identified through thorough multiparameter optimisation. Showing robust in vivo activity in an oxazolone-mediated inflammation model, the compound was selected for development. Following a polymorph screen, the hydrochloride salt was selected and the synthesis was efficiently developed to yield the API in 47% overall yield.
Collapse
Affiliation(s)
- Jean-Guy Boiteau
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France.
| | - Gilles Ouvry
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France.
| | | | - Stéphanie Astri
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Audrey Beillard
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | | | - Laetitia Bonnary
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Claire Bouix-Peter
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Karine Bouquet
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Marilyne Bourotte
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Isabelle Cardinaud
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Catherine Comino
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Benoît Deprez
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Denis Duvert
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Angélique Féret
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | | | - Craig S Harris
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Anne-Pascale Luzy
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Arnaud Mathieu
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Corinne Millois
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Nicolas Orsini
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Jonathan Pascau
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Artur Pinto
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - David Piwnica
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Gaëlle Polge
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Arnaud Reitz
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Kevin Reversé
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Nicolas Rodeville
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Patricia Rossio
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Delphine Spiesse
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Samuel Tabet
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Nathalie Taquet
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Loïc Tomas
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Emmanuel Vial
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Laurent F Hennequin
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| |
Collapse
|
6
|
Ouvry G, Berton Y, Bhurruth-Alcor Y, Bonnary L, Bouix-Peter C, Bouquet K, Bourotte M, Chambon S, Comino C, Deprez B, Duvert D, Duvert G, Hacini-Rachinel F, Harris CS, Luzy AP, Mathieu A, Millois C, Pascau J, Pinto A, Polge G, Reitz A, Reversé K, Rosignoli C, Taquet N, Hennequin LF. Identification of novel TACE inhibitors compatible with topical application. Bioorg Med Chem Lett 2017; 27:1848-1853. [PMID: 28274635 DOI: 10.1016/j.bmcl.2017.02.035] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2017] [Revised: 02/15/2017] [Accepted: 02/16/2017] [Indexed: 12/16/2022]
Abstract
Targeting the Tumor Necrosis Factor α signalling with antibodies has led to a revolution in the treatment of psoriasis. Locally inhibiting Tumor Necrosis Factor α Converting Enzyme (TACE or ADAM17) could potentially mimic those effects and help treat mild to moderate psoriasis, without the reported side effect of systemic TACE inhibitors. Efforts to identify new TACE inhibitors are presented here. Enzymatic SAR as well as ADME and physico-chemistry data are presented. This study culminated in the identification of potent enzymatic inhibitors. Suboptimal cellular activity of this series is discussed in the context of previously published results.
Collapse
Affiliation(s)
- Gilles Ouvry
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France.
| | - Yaël Berton
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | | | - Laetitia Bonnary
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Claire Bouix-Peter
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Karine Bouquet
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Marilyne Bourotte
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Sandrine Chambon
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Catherine Comino
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Benoît Deprez
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Denis Duvert
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Gwenaëlle Duvert
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | | | - Craig S Harris
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Anne-Pascale Luzy
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Arnaud Mathieu
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Corinne Millois
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Jonathan Pascau
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Artur Pinto
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France
| | - Gaëlle Polge
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Arnaud Reitz
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Kevin Reversé
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Carine Rosignoli
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Nathalie Taquet
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| | - Laurent F Hennequin
- Nestlé Skin Health R&D, Les Templiers 2400 Route des Colles, 06410 Biot, France
| |
Collapse
|
7
|
Devale TL, Parikh J, Miniyar P, Sharma P, Shrivastava B, Murumkar P. Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Chem 2017; 70:256-266. [PMID: 28160944 DOI: 10.1016/j.bioorg.2017.01.006] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2016] [Revised: 12/17/2016] [Accepted: 01/15/2017] [Indexed: 02/08/2023]
Abstract
A novel series of substituted N-(2-(2,3-dioxoindolin-1-yl)acetyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide was designed, synthesized and evaluated for in vitro Reverse Transcriptase (RT) inhibitory activity. This series is a combination of peculiar structural features from leading scaffolds of [(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) and oxyindole. In vitro screening led to identification of two hybrids (9c and 9d) possessing higher RT inhibitory activity than the standard rilpivirine. Docking study was performed to study the binding orientations of synthesized hybrids towards RT enzyme.
Collapse
Affiliation(s)
- Titiksh L Devale
- Jaipur National University, Jagatpura, Jaipur, India; Sinhgad Institute of Pharmacy, Narhe, Pune, India.
| | | | | | - Pankaj Sharma
- Jaipur National University, Jagatpura, Jaipur, India.
| | | | - Prashant Murumkar
- Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, India.
| |
Collapse
|
8
|
Udechukwu MC, Tsopmo A, Mawhinney H, He R, Kienesberger PC, Udenigwe CC. Inhibition of ADAM17/TACE activity by zinc-chelating rye secalin-derived tripeptides and analogues. RSC Adv 2017. [DOI: 10.1039/c6ra26678a] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Rye secalin-derived cysteine-containing tripeptides and analogues inhibited ADAM17 activity via active site zinc coordination, hydrogen bonds and hydrophobic interactions.
Collapse
Affiliation(s)
- M. Chinonye Udechukwu
- Department of Plant, Food, and Environmental Sciences
- Faculty of Agriculture
- Dalhousie University
- Truro
- Canada
| | - Apollinaire Tsopmo
- Food Science and Nutrition
- Department of Chemistry
- Faculty of Science
- Carleton University
- Ottawa
| | - Hannah Mawhinney
- Department of Plant, Food, and Environmental Sciences
- Faculty of Agriculture
- Dalhousie University
- Truro
- Canada
| | - Rong He
- Department of Food Science and Engineering
- Nanjing University of Finance and Economics
- Nanjing City
- China
| | - Petra C. Kienesberger
- Department of Biochemistry and Molecular Biology
- Faculty of Medicine
- Dalhousie University
- Saint John
- Canada
| | - Chibuike C. Udenigwe
- Department of Plant, Food, and Environmental Sciences
- Faculty of Agriculture
- Dalhousie University
- Truro
- Canada
| |
Collapse
|
9
|
Madoux F, Dreymuller D, Pettiloud JP, Santos R, Becker-Pauly C, Ludwig A, Fields GB, Bannister T, Spicer TP, Cudic M, Scampavia LD, Minond D. Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate. Sci Rep 2016; 6:11. [PMID: 28442704 DOI: 10.1038/s41598-016-0013-4] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Accepted: 08/12/2016] [Indexed: 02/01/2023] Open
Abstract
ADAM10 and ADAM17 have been shown to contribute to the acquired drug resistance of HER2-positive breast cancer in response to trastuzumab. The majority of ADAM10 and ADAM17 inhibitor development has been focused on the discovery of compounds that bind the active site zinc, however, in recent years, there has been a shift from active site to secondary substrate binding site (exosite) inhibitor discovery in order to identify non-zinc-binding molecules. In the present work a glycosylated, exosite-binding substrate of ADAM10 and ADAM17 was utilized to screen 370,276 compounds from the MLPCN collection. As a result of this uHTS effort, a selective, time-dependent, non-zinc-binding inhibitor of ADAM10 with Ki = 883 nM was discovered. This compound exhibited low cell toxicity and was able to selectively inhibit shedding of known ADAM10 substrates in several cell-based models. We hypothesize that differential glycosylation of these cognate substrates is the source of selectivity of our novel inhibitor. The data indicate that this novel inhibitor can be used as an in vitro and, potentially, in vivo, probe of ADAM10 activity. Additionally, results of the present and prior studies strongly suggest that glycosylated substrate are applicable as screening agents for discovery of selective ADAM probes and therapeutics.
Collapse
|
10
|
Borah PK, Chakraborty S, Jha AN, Rajkhowa S, Duary RK. In silico approaches and proportional odds model towards identifying selective ADAM17 inhibitors from anti-inflammatory natural molecules. J Mol Graph Model 2016; 70:129-139. [PMID: 27723561 DOI: 10.1016/j.jmgm.2016.10.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 09/30/2016] [Accepted: 10/03/2016] [Indexed: 11/16/2022]
Abstract
ADAM metallopeptidase domain 17 (ADAM17) is an attractive target for the development of new anti-inflammatory drugs. We aimed to identify selective inhibitors of ADAM17 against matrix metalloproteinase enzymes (MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-13, and MMP-16) which have substantial structural similarity. Target proteins were docked with 29 anti-inflammatory natural molecule ligands and a known selective inhibitor IK682. The ligands were screened based on Lipinski rules, interaction with the ADAM17 active site cavity, and then ranked using the proportional odds model multinomial logistic regression. Silymarin was the most selective inhibitor of ADAM17 exhibiting H-bonding with Glu 406, Gly 349, Glu 398, Asn 447, Tyr 433, and Lys 432. Molecular dynamics simulations were carried out for 10ns. The root mean square deviation (RMSD), root mean squared fluctuations (RMSF), radius of gyration (Rg), solvent accessible surface area (SASA), and H-bonding indicated the induced metastability. A comparison of the principal component analysis revealed that the silymarin complex also explored lesser region compared to IK682 complex. A control study on ADAM17 protein (2OI0) is included. These observations present silymarin (widely present in plants such as milk thistle (Silybum maianum), wild artichokes (Cynara cardunculus), turmeric (Curcuma longa) roots, coriander (Coriandrum sativum) seeds, etc.) as a promising natural template for development of ADAM17 selective drugs.
Collapse
Affiliation(s)
- Pallab Kumar Borah
- School of Engineering, Dept. of Food Engineering and Technology, Tezpur University, Napaam, Tezpur, Assam 784028, India
| | - Sourav Chakraborty
- School of Engineering, Dept. of Food Engineering and Technology, Tezpur University, Napaam, Tezpur, Assam 784028, India
| | - Anupam N Jha
- School of Sciences, Dept. of Molecular Biology and Biotechnology, Tezpur University, Napaam, Tezpur, Assam 784028, India
| | - Sanchaita Rajkhowa
- School of Sciences, Dept. of Chemical Science, Tezpur University, Napaam, Tezpur, Assam 784028, India
| | - Raj Kumar Duary
- School of Engineering, Dept. of Food Engineering and Technology, Tezpur University, Napaam, Tezpur, Assam 784028, India.
| |
Collapse
|
11
|
Abstract
Inhibitors of tumor necrosis factor-α converting enzyme (TACE) have potential as therapeutics for various diseases. Many small molecule inhibitors, however, exhibit poor specificity profiles because they target the highly conserved catalytic cleft of TACE. We report for the first time the molecular interaction of a highly specific anti-TACE antagonistic antibody (MEDI3622). We characterized the binding of MEDI3622 using mutagenesis, as well as structural modeling and docking approaches. We show that MEDI3622 recognizes a unique surface loop of sIVa-sIVb β-hairpin on TACE M-domain, but does not interact with the conserved catalytic cleft or its nearby regions. The exquisite specificity of MEDI3622 is mediated by this distinct structural feature on the TACE M-domain. These findings may aid the design of antibody therapies against TACE.
Collapse
Affiliation(s)
- Li Peng
- a Department of Antibody Discovery and Protein Engineering , MedImmune , Gaithersburg , MD , USA
| | - Kimberly Cook
- a Department of Antibody Discovery and Protein Engineering , MedImmune , Gaithersburg , MD , USA
| | - Linda Xu
- a Department of Antibody Discovery and Protein Engineering , MedImmune , Gaithersburg , MD , USA
| | - Li Cheng
- a Department of Antibody Discovery and Protein Engineering , MedImmune , Gaithersburg , MD , USA
| | - Melissa Damschroder
- a Department of Antibody Discovery and Protein Engineering , MedImmune , Gaithersburg , MD , USA
| | - Changshou Gao
- a Department of Antibody Discovery and Protein Engineering , MedImmune , Gaithersburg , MD , USA
| | - Herren Wu
- a Department of Antibody Discovery and Protein Engineering , MedImmune , Gaithersburg , MD , USA
| | - William F Dall'Acqua
- a Department of Antibody Discovery and Protein Engineering , MedImmune , Gaithersburg , MD , USA
| |
Collapse
|
12
|
Yadav MR, Barmade MA, Tamboli RS, Murumkar PR. Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer. Eur J Med Chem 2015; 105:1-38. [DOI: 10.1016/j.ejmech.2015.09.038] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Revised: 09/29/2015] [Accepted: 09/30/2015] [Indexed: 01/05/2023]
|
13
|
Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D. SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes. J Med Chem 2015; 58:5808-24. [PMID: 26192023 DOI: 10.1021/acs.jmedchem.5b00354] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
ADAM17 is implicated in several debilitating diseases. However, drug discovery efforts targeting ADAM17 have failed due to the utilization of zinc-binding inhibitors. We previously reported discovery of highly selective nonzinc-binding exosite-targeting inhibitors of ADAM17 that exhibited not only enzyme isoform selectivity but synthetic substrate selectivity as well ( J. Biol. Chem. 2013, 288, 22871). As a result of SAR studies presented herein, we obtained several highly selective ADAM17 inhibitors, six of which were further characterized in biochemical and cell-based assays. Lead compounds exhibited low cellular toxicity and high potency and selectivity for ADAM17. In addition, several of the leads inhibited ADAM17 in a substrate-selective manner, which has not been previously documented for inhibitors of the ADAM family. These findings suggest that targeting exosites of ADAM17 can be used to obtain highly desirable substrate-selective inhibitors. Additionally, current inhibitors can be used as probes of biological activity of ADAM17 in various in vitro and, potentially, in vivo systems.
Collapse
Affiliation(s)
- Anna M Knapinska
- ∥Florida Atlantic University, 5353 Parkside Drive, Jupiter, Florida 33458, United States
| | - Daniela Dreymuller
- ⊥Institute of Pharmacology and Toxicology, RWTH Aachen University, Wendlingweg 2, 52074 Aachen, Germany
| | - Andreas Ludwig
- ⊥Institute of Pharmacology and Toxicology, RWTH Aachen University, Wendlingweg 2, 52074 Aachen, Germany
| | - Lyndsay Smith
- ∥Florida Atlantic University, 5353 Parkside Drive, Jupiter, Florida 33458, United States
| | - Vladislav Golubkov
- ‡Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Anjum Sohail
- §Wayne State University, 8200 Scott Hall, 540 East Canfield Avenue, Detroit, Michigan 48201, United States
| | - Rafael Fridman
- §Wayne State University, 8200 Scott Hall, 540 East Canfield Avenue, Detroit, Michigan 48201, United States
| | - Marc Giulianotti
- †Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, Florida 34987, United States.,∇Department of Chemistry, Center for Drug Discovery and Innovation, University of South Florida, Tampa, Florida 33612, United States
| | - Travis M LaVoi
- †Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, Florida 34987, United States
| | - Richard A Houghten
- †Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, Florida 34987, United States
| | - Gregg B Fields
- ∥Florida Atlantic University, 5353 Parkside Drive, Jupiter, Florida 33458, United States.,#The Scripps Research Institute/Scripps Florida, 130 Scripps Way, Jupiter, Florida 33458, United States
| | - Dmitriy Minond
- †Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, Florida 34987, United States
| |
Collapse
|
14
|
Rios-Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, Cheng L, Du Q, Schifferli K, Rothstein R, Leow CC, Heidbrink-Thompson J, Jin X, Gao C, Friedman J, Wilkinson B, Damschroder M, Pierce AJ, Hollingsworth RE, Tice DA, Michelotti EF. A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways. Mol Cancer Ther 2015; 14:1637-49. [PMID: 25948294 DOI: 10.1158/1535-7163.mct-14-1040] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2014] [Accepted: 04/30/2015] [Indexed: 11/16/2022]
Abstract
ADAM17 is the primary sheddase for HER pathway ligands. We report the discovery of a potent and specific ADAM17 inhibitory antibody, MEDI3622, which induces tumor regression or stasis in many EGFR-dependent tumor models. The inhibitory activity of MEDI3622 correlated with EGFR activity both in a series of tumor models across several indications as well in as a focused set of head and neck patient-derived xenograft models. The antitumor activity of MEDI3622 was superior to that of EGFR/HER pathway inhibitors in the OE21 esophageal model and the COLO205 colorectal model suggesting additional activity outside of the EGFR pathway. Combination of MEDI3622 and cetuximab in the OE21 model was additive and eradicated tumors. Proteomics analysis revealed novel ADAM17 substrates that function outside of the HER pathways and may contribute toward the antitumor activity of the monoclonal antibody.
Collapse
Affiliation(s)
| | - Darrin Sabol
- Oncology Research, MedImmune, LLC, Gaithersburg, Maryland
| | | | - Dave Stewart
- Oncology Research, MedImmune, LLC, Gaithersburg, Maryland
| | - Linda Xu
- Oncology Research, MedImmune, LLC, Gaithersburg, Maryland
| | | | - Li Cheng
- Oncology Research, MedImmune, LLC, Gaithersburg, Maryland
| | - Qun Du
- Oncology Research, MedImmune, LLC, Gaithersburg, Maryland
| | | | - Ray Rothstein
- Oncology Research, MedImmune, LLC, Gaithersburg, Maryland
| | | | | | - Xiaofang Jin
- Oncology Research, MedImmune, LLC, Gaithersburg, Maryland
| | - Changshou Gao
- Oncology Research, MedImmune, LLC, Gaithersburg, Maryland
| | | | | | | | | | | | - David A Tice
- Oncology Research, MedImmune, LLC, Gaithersburg, Maryland
| | | |
Collapse
|
15
|
Niu A, Wang B, Li YP. TNFα Shedding in Mechanically Stressed Cardiomyocytes is Mediated by Src Activation of TACE. J Cell Biochem 2015; 116:559-65. [DOI: 10.1002/jcb.25006] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Accepted: 10/27/2014] [Indexed: 11/08/2022]
Affiliation(s)
- Airu Niu
- Department of Integrative Biology and Pharmacology; University of Texas Health Science Center; Houston Texas 77030
| | - Bin Wang
- Department of Integrative Biology and Pharmacology; University of Texas Health Science Center; Houston Texas 77030
| | - Yi-Ping Li
- Department of Integrative Biology and Pharmacology; University of Texas Health Science Center; Houston Texas 77030
| |
Collapse
|
16
|
Sarkate AP, Murumkar PR, Lokwani DK, Kandhare AD, Bodhankar SL, Shinde DB, Bothara KG. Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity. SAR QSAR Environ Res 2015; 26:905-923. [PMID: 26588187 DOI: 10.1080/1062936x.2015.1095240] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Tumor necrosis factor-α (TNF-α) converting enzyme (TACE) has been considered one of the principal therapeutic targets for the treatment of TNF-dependent pathologies. Several TACE inhibitors have been reported, but none of them has been successfully passed to phase II clinical trials. In the present work, we attempted to design highly selective new non-hydroxamate sulfonamide TACE inhibitors. The docking study was performed on one of the crystal structures of TACE, selected based on its resolution and R value, to tackle the flexibility issue of the active site. The results allowed us to distinguish the analogues with a higher binding affinity toward the active site of TACE and to identify the substituent of analogues needed for binding with the surrounding site of the enzyme. Finally the analogues were docked on crystal structures of six different matrix metalloproteinases (MMPs) for a selectivity study of TACE over MMPs. Some of these analogues were synthesized and subjected to preliminary testing for in vivo anti-inflammatory activity and TACE inhibitory activity.
Collapse
Affiliation(s)
- A P Sarkate
- a Department of Pharmaceutical Chemistry , Sinhgad Institute of Pharmacy , Pune , Maharashtra , India
| | - P R Murumkar
- a Department of Pharmaceutical Chemistry , Sinhgad Institute of Pharmacy , Pune , Maharashtra , India
| | - D K Lokwani
- b Department of Chemical Technology , Dr. Babasaheb Ambedkar Marathwada University , Aurangabad , Maharashtra , India
| | - A D Kandhare
- c Department of Pharmacology , Poona College of Pharmacy, Bharati Vidyapeeth Deemed University , Pune , Maharashtra , India
| | - S L Bodhankar
- c Department of Pharmacology , Poona College of Pharmacy, Bharati Vidyapeeth Deemed University , Pune , Maharashtra , India
| | - D B Shinde
- b Department of Chemical Technology , Dr. Babasaheb Ambedkar Marathwada University , Aurangabad , Maharashtra , India
| | - K G Bothara
- a Department of Pharmaceutical Chemistry , Sinhgad Institute of Pharmacy , Pune , Maharashtra , India
| |
Collapse
|
17
|
Murumkar PR, Sharma MK, Giridhar R, Yadav MR. Virtual screening-based identification of lead molecules as selective TACE inhibitors. Med Chem Res 2015; 24:226-44. [DOI: 10.1007/s00044-014-1097-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
18
|
Mucke HA. Patent Highlights. Pharm Pat Anal 2014; 3:367-374. [DOI: 10.4155/ppa.14.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development
Collapse
|
19
|
Affiliation(s)
- Barry J Sheane
- University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital,
1E 416, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada ;
- University of Toronto, Department of Medicine, Division of Rheumatology,
Toronto, Canada
| | - Vinod Chandran
- University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto Western Hospital,
1E 416, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada ;
- University of Toronto, Department of Medicine, Division of Rheumatology,
Toronto, Canada
| |
Collapse
|
20
|
Fiaturi N, Ritzkat A, Dammann CE, Castellot JJ, Nielsen HC. Dissociated presenilin-1 and TACE processing of ErbB4 in lung alveolar type II cell differentiation. Biochim Biophys Acta 2014; 1843:797-805. [PMID: 24462774 DOI: 10.1016/j.bbamcr.2014.01.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Revised: 12/18/2013] [Accepted: 01/13/2014] [Indexed: 01/25/2023]
Abstract
Neuregulin (NRG) stimulation of ErbB4 signaling is important for type II cell surfactant synthesis. ErbB4 may mediate gene expression via a non-canonical pathway involving enzymatic cleavage releasing its intracellular domain (4ICD) for nuclear trafficking and gene regulation. The accepted model for release of 4ICD is consecutive cleavage by Tumor necrosis factor alpha Converting Enzyme (TACE) and γ-secretase enzymes. Here, we show that 4ICD mediates surfactant synthesis and its release by γ-secretase is not dependent on previous TACE cleavage. We used siRNA to silence Presenilin-1 (PSEN-1) expression in a mouse lung type II epithelial cell line (MLE12 cells), and both siRNA knockdown and chemical inhibition of TACE. Knockdown of PSEN-1 significantly decreased baseline and NRG-stimulated surfactant phospholipid synthesis, expression of the surfactant proteins SP-B and SP-C, as well as 4ICD levels, with no change in ErbB4 ectodomain shedding. Neither siRNA knockdown nor chemical inhibition of TACE inhibited 4ICD release or surfactant synthesis. PSEN-1 cleavage of ErbB4 for non-canonical signaling through 4ICD release does not require prior cleavage by TACE.
Collapse
|